Algeria Gate: The Saidal Group is speeding up the implementation of several strategic projects at its Constantine sites, as part of a new push to strengthen Algeria’s pharmaceutical sovereignty.

During a working visit, Saidal’s CEO, Younes Bouarara, inspected the Constantine 1 and Constantine 2 units and called for removing obstacles in order to speed up the commissioning of the projects.

The investments include the production of innovative GLP-1-based treatments for type 2 diabetes and obesity, the manufacturing of biosimilars, as well as the development of insulin and vaccine production lines.

These projects are part of the strategy driven by President Abdelmadjid Tebboune to make Algeria less dependent on imports and capable of locally producing high-value-added medicines.

With this new generation of investments, Saïdal aims to take part in a genuine revolution of Algeria’s pharmaceutical industry, built on local production, innovation, and health sovereignty.



